EBMT 2019 | MRD negativity in ALL
Dieter Hoelzer
Dieter Hoelzer, MD, PhD, from the University of Frankfurt, Frankfurt, Germany, explores the importance of MRD negativity in acute lymphoblastic leukemia (ALL). Dr Hoelzer was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
Related videos
2:05
Transplantation in the era of CAR T-cell therapy
Julio Delgado
3:08
Follow-up of the ALLR3 trial: pediatric late bone marrow relapse & lessons learned
Vaskar Saha
2:04
MRD in pediatric ALL: clinical evidence, treatment decisions & outcomes
Vaskar Saha
3:27
CAR-T for ALL: access, eligibility & toxicity
Sara Ghorashian
2:02
CARPALL and AMELIA: ongoing data for CAR-T in ALL
Sara Ghorashian
